Velphoro Tablet, Chewable
Product Images NDC 49230-646

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Velphoro (NDC 49230-646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Medical Care Renal Therapies Group, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Velphoro 01)

A line graph comparing the change from baseline in serum phosphorus levels (mg/dL) over weeks on study treatment for Velphoro (N=694) and Sevelamer Carbonate (N=347). The main graph shows reductions in serum phosphorus over 52 weeks, with Velphoro showing slightly greater decreases. An inset graph displays the withdrawal phase, showing changes in serum phosphorus from week 24 to 27 for Velphoro Maintenance Dose (N=44) and Velphoro Low Dose (N=49), with the low dose group having a greater increase.*

FDA Label Image

Principal Display Panel (500 mg Tablet Bottle Label)

Velphoro 500 mg chewable tablets label displaying sucroferric oxyhydroxide as the active ingredient. The label indicates tablets should be chewed or crushed and contains 90 tablets. Distributed by Fresenius Medical Care Renal Therapies Group, LLC, with storage instructions and barcode also visible.*

FDA Label Image

Principal Display Panel (500 mg Tablet Bottle Carton)

Packaging label for Velphoro 500 mg chewable tablets containing sucroferric oxyhydroxide. The label indicates 90 tablets per package, to be chewed or crushed, for oral use. Distributed by Fresenius Medical Care Renal Therapies Group, LLC, with storage instructions and inactive ingredients listed. The package includes barcode and NDC number 49230-645-51.*

FDA Label Image

Principal Display Panel (250 mg Tablet Bottle Label)

Velphoro 250 mg chewable tablets label showing sucroferric oxyhydroxide as the active ingredient. The label indicates the tablets should be chewed or crushed and the package contains 90 tablets. It includes storage instructions and distribution information by Fresenius Medical Care Renal Therapies Group, LLC, made in Switzerland.*

FDA Label Image

Principal Display Panel (250 mg Tablet Bottle Carton)

Packaging label for Velphoro 250 mg chewable tablets containing sucroferric oxyhydroxide. The label indicates the tablet strength as 250 mg and that 90 tablets are included. It is distributed by Fresenius Medical Care Renal Therapies Group, LLC and manufactured in Switzerland. The label includes storage instructions and inactive ingredients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.